SCHEMBL23756437

SCHEMBL23756437

COC(=O)c1ccc2nc(Cl)c(Cl)cc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ CSNK2A1 P68400 1/20 0.49
▸ ALDH1A1 P00352 4/20 0.48
▸ RHEB Q15382 1/20 0.46
▸ TP53 P04637 1/20 0.45
▸ KDM4E B2RXH2 4/20 0.45
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ XDH P47989 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ PIK3CA P42336 1/20 0.45
▸ PIK3CB P42338 1/20 0.45
▸ PIK3CG P48736 1/20 0.45
▸ PI4KB Q9UBF8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30908511 0.88 CSNK2A1 (0.52) HTTALOX15CSNK2A1ALDH1A1RHEB
SCHEMBL18369634 0.86 HTT (0.52) HTTALOX15ALDH1A1RHEBTP53
SCHEMBL31544152 0.86 HTT (0.52) HTTALOX15CSNK2A1ALDH1A1TP53
SCHEMBL18370845 0.85 HTT (0.51) HTTALOX15CSNK2A1ALDH1A1RHEB
SCHEMBL23774957 0.85 HTT (0.51) HTTALOX15CSNK2A1ALDH1A1RHEB
SCHEMBL31544142 0.84 HTT (0.50) HTTALOX15CSNK2A1ALDH1A1TP53
SCHEMBL31544181 0.84 CYP1A2 (0.51) HTTALOX15CSNK2A1ALDH1A1KDM4E
SCHEMBL31544230 0.84 CYP1A2 (0.51) HTTALOX15CSNK2A1ALDH1A1KDM4E
SCHEMBL31544141 0.82 ALDH1A1 (0.51) HTTALOX15CSNK2A1ALDH1A1RHEB
SCHEMBL25519701 0.82 HTT (0.49) HTTALOX15CSNK2A1ALDH1A1RHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 — — US disclosed
US-20230159510-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2023-05-25 — — US disclosed
EP-4103558-A1 NOVEL PRMT5 INHIBITORS Amgen Inc. (US) 2022-12-21 — — EP disclosed
WO-2021163344-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2021-08-19 — — WO disclosed
WO-2021163344-A1 NOVEL PRMT5 INHIBITORS AMGEN INC. (US) 2021-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159510-A1 NOVEL PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 HTT 3702/4885ALOX15 3322/4885CSNK2A1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback